Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients
Status:
Recruiting
Trial end date:
2026-02-28
Target enrollment:
Participant gender:
Summary
This is a single-centre, non-randomized, open label phase II trial to be conducted at the
National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be
eligible to enrol.
The investigators hypothesize the anticancer activity of low dose OXIRI (LD-OXIRI) regimen
comprising of metronomic oxaliplatin (O) and metronomic capecitabine (xeloda; X) in
combination with UGT1A1-directed dosing of irinotecan (IRI) to be a tolerable regimen in
patients with advanced PDAC and will lead to a favourable response rate.
Patients will be prospectively enrolled in two stages - In stage 1, patients will be
recruited and evaluated for response and toxicity. In stage 2, more patients will be
recruited for further evaluation of response and toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Centre, Singapore
Collaborator:
National Medical Research Council (NMRC), Singapore